{"transactions":[{"id":1306624,"issuer":{"id":84243,"kind":"organization","name":"Poseida Therapeutics, Inc.","symbol":"PSTX"},"owners":[{"id":84286,"kind":"person","name":"Gergen Mark J","position":1,"cik":"0001373110","reported_name":"Gergen Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-01-08T14:08:47.000Z","date":"2025-01-08","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":172600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option (the \"Option Consideration\"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount, but less than $13.00 (any such option, an \"Underwater Option\"), [continues to Footnote 5]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"[Continues from Footnote 4] such Underwater Option was not entitled to any payment of the Cash Amount in respect thereof and each Underwater Option was converted into the right to receive the CVR included in the Option Consideration  with respect to each Share underlying such Underwater Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (a) the total number of Shares underlying such Underwater Option, multiplied by (b) the amount, if any, by which (1) the Cash Amount plus the amount of such milestone payment plus the amount of any other milestone payments that previously became due and payable under the terms of the CVR Agreement exceeds (2) the exercise price per Share with respect to such Underwater Option plus the Milestone Payment Amounts (as such term is defined in the CVR Agreement), [continues to Footnote 6]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"[Continues from Footnote 5] if any, previously paid pursuant to the CVR Agreement in respect of each CVR granted in respect of such Underwater Option; provided further, that any Option with an exercise price that was equal to or greater than $13.00, was cancelled immediately prior to the effective time of the Merger without any payment being made in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":3.38,"expiration_date":"2034-01-01","underlying":"Common Stock","underlying_shares":172600},"source":{"system":"sec-edgar","filing":"0001415889-25-001081","document":"form4-01082025_070143.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1661460/000141588925001081/form4-01082025_070143.xml","form_type":"4"}},{"id":1306623,"issuer":{"id":84243,"kind":"organization","name":"Poseida Therapeutics, Inc.","symbol":"PSTX"},"owners":[{"id":84286,"kind":"person","name":"Gergen Mark J","position":1,"cik":"0001373110","reported_name":"Gergen Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-01-08T14:08:47.000Z","date":"2025-01-08","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":364060,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option (the \"Option Consideration\"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount, but less than $13.00 (any such option, an \"Underwater Option\"), [continues to Footnote 5]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"[Continues from Footnote 4] such Underwater Option was not entitled to any payment of the Cash Amount in respect thereof and each Underwater Option was converted into the right to receive the CVR included in the Option Consideration  with respect to each Share underlying such Underwater Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (a) the total number of Shares underlying such Underwater Option, multiplied by (b) the amount, if any, by which (1) the Cash Amount plus the amount of such milestone payment plus the amount of any other milestone payments that previously became due and payable under the terms of the CVR Agreement exceeds (2) the exercise price per Share with respect to such Underwater Option plus the Milestone Payment Amounts (as such term is defined in the CVR Agreement), [continues to Footnote 6]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"[Continues from Footnote 5] if any, previously paid pursuant to the CVR Agreement in respect of each CVR granted in respect of such Underwater Option; provided further, that any Option with an exercise price that was equal to or greater than $13.00, was cancelled immediately prior to the effective time of the Merger without any payment being made in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":5.35,"expiration_date":"2033-02-28","underlying":"Common Stock","underlying_shares":364060},"source":{"system":"sec-edgar","filing":"0001415889-25-001081","document":"form4-01082025_070143.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1661460/000141588925001081/form4-01082025_070143.xml","form_type":"4"}},{"id":1306622,"issuer":{"id":84243,"kind":"organization","name":"Poseida Therapeutics, Inc.","symbol":"PSTX"},"owners":[{"id":84286,"kind":"person","name":"Gergen Mark J","position":1,"cik":"0001373110","reported_name":"Gergen Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-01-08T14:08:47.000Z","date":"2025-01-08","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":518500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option (the \"Option Consideration\"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount, but less than $13.00 (any such option, an \"Underwater Option\"), [continues to Footnote 5]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"[Continues from Footnote 4] such Underwater Option was not entitled to any payment of the Cash Amount in respect thereof and each Underwater Option was converted into the right to receive the CVR included in the Option Consideration  with respect to each Share underlying such Underwater Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (a) the total number of Shares underlying such Underwater Option, multiplied by (b) the amount, if any, by which (1) the Cash Amount plus the amount of such milestone payment plus the amount of any other milestone payments that previously became due and payable under the terms of the CVR Agreement exceeds (2) the exercise price per Share with respect to such Underwater Option plus the Milestone Payment Amounts (as such term is defined in the CVR Agreement), [continues to Footnote 6]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"[Continues from Footnote 5] if any, previously paid pursuant to the CVR Agreement in respect of each CVR granted in respect of such Underwater Option; provided further, that any Option with an exercise price that was equal to or greater than $13.00, was cancelled immediately prior to the effective time of the Merger without any payment being made in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":4.75,"expiration_date":"2032-01-31","underlying":"Common Stock","underlying_shares":518500},"source":{"system":"sec-edgar","filing":"0001415889-25-001081","document":"form4-01082025_070143.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1661460/000141588925001081/form4-01082025_070143.xml","form_type":"4"}},{"id":1306621,"issuer":{"id":84243,"kind":"organization","name":"Poseida Therapeutics, Inc.","symbol":"PSTX"},"owners":[{"id":84286,"kind":"person","name":"Gergen Mark J","position":1,"cik":"0001373110","reported_name":"Gergen Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-01-08T14:08:47.000Z","date":"2025-01-08","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":342000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option (the \"Option Consideration\"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount, but less than $13.00 (any such option, an \"Underwater Option\"), [continues to Footnote 5]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"[Continues from Footnote 4] such Underwater Option was not entitled to any payment of the Cash Amount in respect thereof and each Underwater Option was converted into the right to receive the CVR included in the Option Consideration  with respect to each Share underlying such Underwater Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (a) the total number of Shares underlying such Underwater Option, multiplied by (b) the amount, if any, by which (1) the Cash Amount plus the amount of such milestone payment plus the amount of any other milestone payments that previously became due and payable under the terms of the CVR Agreement exceeds (2) the exercise price per Share with respect to such Underwater Option plus the Milestone Payment Amounts (as such term is defined in the CVR Agreement), [continues to Footnote 6]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"[Continues from Footnote 5] if any, previously paid pursuant to the CVR Agreement in respect of each CVR granted in respect of such Underwater Option; provided further, that any Option with an exercise price that was equal to or greater than $13.00, was cancelled immediately prior to the effective time of the Merger without any payment being made in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":9.15,"expiration_date":"2031-02-03","underlying":"Common Stock","underlying_shares":342000},"source":{"system":"sec-edgar","filing":"0001415889-25-001081","document":"form4-01082025_070143.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1661460/000141588925001081/form4-01082025_070143.xml","form_type":"4"}},{"id":1306620,"issuer":{"id":84243,"kind":"organization","name":"Poseida Therapeutics, Inc.","symbol":"PSTX"},"owners":[{"id":84286,"kind":"person","name":"Gergen Mark J","position":1,"cik":"0001373110","reported_name":"Gergen Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-01-08T14:08:47.000Z","date":"2025-01-08","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option (the \"Option Consideration\"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount, but less than $13.00 (any such option, an \"Underwater Option\"), [continues to Footnote 5]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"[Continues from Footnote 4] such Underwater Option was not entitled to any payment of the Cash Amount in respect thereof and each Underwater Option was converted into the right to receive the CVR included in the Option Consideration  with respect to each Share underlying such Underwater Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (a) the total number of Shares underlying such Underwater Option, multiplied by (b) the amount, if any, by which (1) the Cash Amount plus the amount of such milestone payment plus the amount of any other milestone payments that previously became due and payable under the terms of the CVR Agreement exceeds (2) the exercise price per Share with respect to such Underwater Option plus the Milestone Payment Amounts (as such term is defined in the CVR Agreement), [continues to Footnote 6]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"[Continues from Footnote 5] if any, previously paid pursuant to the CVR Agreement in respect of each CVR granted in respect of such Underwater Option; provided further, that any Option with an exercise price that was equal to or greater than $13.00, was cancelled immediately prior to the effective time of the Merger without any payment being made in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":16,"expiration_date":"2030-07-08","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001415889-25-001081","document":"form4-01082025_070143.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1661460/000141588925001081/form4-01082025_070143.xml","form_type":"4"}},{"id":1306619,"issuer":{"id":84243,"kind":"organization","name":"Poseida Therapeutics, Inc.","symbol":"PSTX"},"owners":[{"id":84286,"kind":"person","name":"Gergen Mark J","position":1,"cik":"0001373110","reported_name":"Gergen Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-01-08T14:08:47.000Z","date":"2025-01-08","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":48115,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option (the \"Option Consideration\"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount, but less than $13.00 (any such option, an \"Underwater Option\"), [continues to Footnote 5]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"[Continues from Footnote 4] such Underwater Option was not entitled to any payment of the Cash Amount in respect thereof and each Underwater Option was converted into the right to receive the CVR included in the Option Consideration  with respect to each Share underlying such Underwater Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (a) the total number of Shares underlying such Underwater Option, multiplied by (b) the amount, if any, by which (1) the Cash Amount plus the amount of such milestone payment plus the amount of any other milestone payments that previously became due and payable under the terms of the CVR Agreement exceeds (2) the exercise price per Share with respect to such Underwater Option plus the Milestone Payment Amounts (as such term is defined in the CVR Agreement), [continues to Footnote 6]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"[Continues from Footnote 5] if any, previously paid pursuant to the CVR Agreement in respect of each CVR granted in respect of such Underwater Option; provided further, that any Option with an exercise price that was equal to or greater than $13.00, was cancelled immediately prior to the effective time of the Merger without any payment being made in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":12.23,"expiration_date":"2029-12-10","underlying":"Common Stock","underlying_shares":48115},"source":{"system":"sec-edgar","filing":"0001415889-25-001081","document":"form4-01082025_070143.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1661460/000141588925001081/form4-01082025_070143.xml","form_type":"4"}},{"id":1306618,"issuer":{"id":84243,"kind":"organization","name":"Poseida Therapeutics, Inc.","symbol":"PSTX"},"owners":[{"id":84286,"kind":"person","name":"Gergen Mark J","position":1,"cik":"0001373110","reported_name":"Gergen Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-01-08T14:08:47.000Z","date":"2025-01-08","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":240721,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option (the \"Option Consideration\"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount, but less than $13.00 (any such option, an \"Underwater Option\"), [continues to Footnote 5]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"[Continues from Footnote 4] such Underwater Option was not entitled to any payment of the Cash Amount in respect thereof and each Underwater Option was converted into the right to receive the CVR included in the Option Consideration  with respect to each Share underlying such Underwater Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (a) the total number of Shares underlying such Underwater Option, multiplied by (b) the amount, if any, by which (1) the Cash Amount plus the amount of such milestone payment plus the amount of any other milestone payments that previously became due and payable under the terms of the CVR Agreement exceeds (2) the exercise price per Share with respect to such Underwater Option plus the Milestone Payment Amounts (as such term is defined in the CVR Agreement), [continues to Footnote 6]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"[Continues from Footnote 5] if any, previously paid pursuant to the CVR Agreement in respect of each CVR granted in respect of such Underwater Option; provided further, that any Option with an exercise price that was equal to or greater than $13.00, was cancelled immediately prior to the effective time of the Merger without any payment being made in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":2.78,"expiration_date":"2028-03-01","underlying":"Common Stock","underlying_shares":240721},"source":{"system":"sec-edgar","filing":"0001415889-25-001081","document":"form4-01082025_070143.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1661460/000141588925001081/form4-01082025_070143.xml","form_type":"4"}},{"id":1306617,"issuer":{"id":84243,"kind":"organization","name":"Poseida Therapeutics, Inc.","symbol":"PSTX"},"owners":[{"id":84286,"kind":"person","name":"Gergen Mark J","position":1,"cik":"0001373110","reported_name":"Gergen Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-01-08T14:08:47.000Z","date":"2025-01-08","kind":"other","planned":false,"acquired":false,"shares":636726,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of November 25, 2024, by and among Poseida Therapeutics, Inc. (the \"Issuer\"), Roche Holdings, Inc. (\"Parent\") and Blue Giant Acquisition Corp., a wholly owned subsidiary of Parent (\"Merger Sub\").  On January 8, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a \"Share\") for an offer price of (i) $9.00 per Share in cash (the \"Cash Amount\"), and (ii) one non-tradeable contingent value right (each, a \"CVR\") representing the right to receive certain contingent payments of up to an aggregate amount of $4.00 per Share, [continues to Footnote 2]"},{"field":"shares","element":"transactionShares","label":"F2","text":"[continues from Footnote 1] in cash, upon the achievement of specified milestones, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the \"CVR Agreement\"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the \"Offer Price\").  Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price."},{"field":"shares","element":"transactionShares","label":"F3","text":"Includes 3,000 shares acquired by the Reporting Person under the Issuer's 2020 Employee Stock Purchase Plan (the \"ESPP\") on March 20, 2024 and 3,000 shares acquired by the Reporting Person under the ESPP on September 20, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of November 25, 2024, by and among Poseida Therapeutics, Inc. (the \"Issuer\"), Roche Holdings, Inc. (\"Parent\") and Blue Giant Acquisition Corp., a wholly owned subsidiary of Parent (\"Merger Sub\").  On January 8, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a \"Share\") for an offer price of (i) $9.00 per Share in cash (the \"Cash Amount\"), and (ii) one non-tradeable contingent value right (each, a \"CVR\") representing the right to receive certain contingent payments of up to an aggregate amount of $4.00 per Share, [continues to Footnote 2]"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"[continues from Footnote 1] in cash, upon the achievement of specified milestones, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the \"CVR Agreement\"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the \"Offer Price\").  Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001415889-25-001081","document":"form4-01082025_070143.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1661460/000141588925001081/form4-01082025_070143.xml","form_type":"4"}},{"id":1314730,"issuer":{"id":84243,"kind":"organization","name":"Poseida Therapeutics, Inc.","symbol":"PSTX"},"owners":[{"id":84286,"kind":"person","name":"Gergen Mark J","position":1,"cik":"0001373110","reported_name":"Gergen Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2025-01-03T20:24:17.000Z","date":"2025-01-02","kind":"tax_withholding","planned":false,"acquired":false,"shares":23313,"price":9.6,"value":223804.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of Restricted Stock Unit Awards granted to the Reporting Person on January 2, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 2,748 shares acquired by the Reporting Person under the Issuer's 2020 Employee Stock Purchase Plan (the \"ESPP\") on January 2, 2025."}],"balance_after":630726,"source":{"system":"sec-edgar","filing":"0000950170-25-001527","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1661460/000095017025001527/ownership.xml","form_type":"4"}},{"id":1335588,"issuer":{"id":84243,"kind":"organization","name":"Poseida Therapeutics, Inc.","symbol":"PSTX"},"owners":[{"id":84286,"kind":"person","name":"Gergen Mark J","position":1,"cik":"0001373110","reported_name":"Gergen Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2024-12-11T17:17:56.000Z","date":"2024-12-10","kind":"exercise","planned":true,"acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option is fully vested and exerciseable."}],"balance_after":96372,"derivative":{"exercise_price":2.781,"expiration_date":"2028-03-01","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000950170-24-135466","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1661460/000095017024135466/ownership.xml","form_type":"4"}},{"id":1335587,"issuer":{"id":84243,"kind":"organization","name":"Poseida Therapeutics, Inc.","symbol":"PSTX"},"owners":[{"id":84286,"kind":"person","name":"Gergen Mark J","position":1,"cik":"0001373110","reported_name":"Gergen Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2024-12-11T17:17:56.000Z","date":"2024-12-10","kind":"sale","planned":true,"acquired":false,"shares":30000,"price":9.4622,"value":283866.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sale reported in this Form 4 were effected pusuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 21, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.44 to $9.49 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":651291,"source":{"system":"sec-edgar","filing":"0000950170-24-135466","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1661460/000095017024135466/ownership.xml","form_type":"4"}},{"id":1335586,"issuer":{"id":84243,"kind":"organization","name":"Poseida Therapeutics, Inc.","symbol":"PSTX"},"owners":[{"id":84286,"kind":"person","name":"Gergen Mark J","position":1,"cik":"0001373110","reported_name":"Gergen Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2024-12-11T17:17:56.000Z","date":"2024-12-10","kind":"exercise","planned":true,"acquired":true,"shares":30000,"price":2.781,"value":83430.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sale reported in this Form 4 were effected pusuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 21, 2024."}],"balance_after":681291,"source":{"system":"sec-edgar","filing":"0000950170-24-135466","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1661460/000095017024135466/ownership.xml","form_type":"4"}},{"id":1349366,"issuer":{"id":84243,"kind":"organization","name":"Poseida Therapeutics, Inc.","symbol":"PSTX"},"owners":[{"id":84286,"kind":"person","name":"Gergen Mark J","position":1,"cik":"0001373110","reported_name":"Gergen Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2024-11-27T19:39:26.000Z","date":"2024-11-26","kind":"exercise","planned":true,"acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option is fully vested and exerciseable."}],"balance_after":126372,"derivative":{"exercise_price":2.781,"expiration_date":"2028-03-01","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000950170-24-131665","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1661460/000095017024131665/ownership.xml","form_type":"4"}},{"id":1349365,"issuer":{"id":84243,"kind":"organization","name":"Poseida Therapeutics, Inc.","symbol":"PSTX"},"owners":[{"id":84286,"kind":"person","name":"Gergen Mark J","position":1,"cik":"0001373110","reported_name":"Gergen Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2024-11-27T19:39:26.000Z","date":"2024-11-26","kind":"sale","planned":true,"acquired":false,"shares":30000,"price":9.27,"value":278100.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sale reported in this Form 4 were effected pusuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 21, 2024."}],"balance_after":651291,"source":{"system":"sec-edgar","filing":"0000950170-24-131665","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1661460/000095017024131665/ownership.xml","form_type":"4"}},{"id":1349364,"issuer":{"id":84243,"kind":"organization","name":"Poseida Therapeutics, Inc.","symbol":"PSTX"},"owners":[{"id":84286,"kind":"person","name":"Gergen Mark J","position":1,"cik":"0001373110","reported_name":"Gergen Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2024-11-27T19:39:26.000Z","date":"2024-11-26","kind":"exercise","planned":true,"acquired":true,"shares":30000,"price":2.781,"value":83430.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercise and sale reported in this Form 4 were effected pusuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 21, 2024."}],"balance_after":681291,"source":{"system":"sec-edgar","filing":"0000950170-24-131665","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1661460/000095017024131665/ownership.xml","form_type":"4"}},{"id":1603087,"issuer":{"id":84243,"kind":"organization","name":"Poseida Therapeutics, Inc.","symbol":"PSTX"},"owners":[{"id":84286,"kind":"person","name":"Gergen Mark J","position":1,"cik":"0001373110","reported_name":"Gergen Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2024-03-04T17:18:59.000Z","date":"2024-03-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":34157,"price":4.13,"value":141068.41,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a Restricted Stock Unit Award granted to the Reporting Person on March 1, 2023."}],"balance_after":651291,"source":{"system":"sec-edgar","filing":"0000950170-24-024922","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1661460/000095017024024922/ownership.xml","form_type":"4"}},{"id":1661703,"issuer":{"id":84243,"kind":"organization","name":"Poseida Therapeutics, Inc.","symbol":"PSTX"},"owners":[{"id":84286,"kind":"person","name":"Gergen Mark J","position":1,"cik":"0001373110","reported_name":"Gergen Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2024-02-02T20:51:25.000Z","date":"2024-02-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":47162,"price":3.41,"value":160822.42,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a Restricted Stock Unit Award granted to the Reporting Person on February 1, 2022."}],"balance_after":685448,"source":{"system":"sec-edgar","filing":"0000950170-24-010943","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1661460/000095017024010943/ownership.xml","form_type":"4"}},{"id":1687803,"issuer":{"id":84243,"kind":"organization","name":"Poseida Therapeutics, Inc.","symbol":"PSTX"},"owners":[{"id":84286,"kind":"person","name":"Gergen Mark J","position":1,"cik":"0001373110","reported_name":"Gergen Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Option (Right to buy)","published_at":"2024-01-04T16:02:14.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":172600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to the stock option will vest and become exercisable on the six-month anniversary of January 1, 2024, and the remaining shares will vest in 18 equal monthly installments thereafter."}],"balance_after":172600,"derivative":{"exercise_price":3.38,"expiration_date":"2034-01-01","underlying":"Common Stock","underlying_shares":172600},"source":{"system":"sec-edgar","filing":"0000950170-24-001831","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1661460/000095017024001831/ownership.xml","form_type":"4"}},{"id":1687802,"issuer":{"id":84243,"kind":"organization","name":"Poseida Therapeutics, Inc.","symbol":"PSTX"},"owners":[{"id":84286,"kind":"person","name":"Gergen Mark J","position":1,"cik":"0001373110","reported_name":"Gergen Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2024-01-04T16:02:14.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares issuable upon the vesting of restricted stock units granted pursuant to the Issuer's Equity Incentive Plan. The RSUs are scheduled to vest 50% on each of the one-year and two-year anniversary of January 1, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 3,000 shares acquired by the Reporting Person under the Issuer's 2020 Employee Stock Purchase Plan (the \"ESPP\") on March 20, 2023 and 3,000 shares acquired by the Reporting Person under the ESPP on September 20, 2023."}],"balance_after":732610,"source":{"system":"sec-edgar","filing":"0000950170-24-001831","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1661460/000095017024001831/ownership.xml","form_type":"4"}},{"id":1979508,"issuer":{"id":84243,"kind":"organization","name":"Poseida Therapeutics, Inc.","symbol":"PSTX"},"owners":[{"id":84286,"kind":"person","name":"Gergen Mark J","position":1,"cik":"0001373110","reported_name":"Gergen Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2023-03-02T18:17:46.000Z","date":"2023-03-01","kind":"grant","acquired":true,"shares":364060,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"12.5% of the shares subject to the stock option will vest and become exercisable on the six-month anniversary of the grant date listed in column 3 above, and the remaining shares will vest in 42 equal monthly installments thereafter."}],"balance_after":364060,"derivative":{"exercise_price":5.35,"expiration_date":"2033-02-28","underlying":"Common Stock","underlying_shares":364060},"source":{"system":"sec-edgar","filing":"0001209191-23-014898","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1661460/000120919123014898/doc4.xml","form_type":"4"}},{"id":1979507,"issuer":{"id":84243,"kind":"organization","name":"Poseida Therapeutics, Inc.","symbol":"PSTX"},"owners":[{"id":84286,"kind":"person","name":"Gergen Mark J","position":1,"cik":"0001373110","reported_name":"Gergen Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-03-02T18:17:46.000Z","date":"2023-03-01","kind":"grant","acquired":true,"shares":269586,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares issuable upon the vesting of restricted stock units granted pursuant to the Issuer's Equity Incentive Plan. The RSUs are scheduled to vest in four equal annual installments."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,710 shares acquired by the Reporting Person under the Issuer's 2020 Employee Stock Purchase Plan on September 20, 2021."}],"balance_after":601610,"source":{"system":"sec-edgar","filing":"0001209191-23-014898","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1661460/000120919123014898/doc4.xml","form_type":"4"}},{"id":2032974,"issuer":{"id":84243,"kind":"organization","name":"Poseida Therapeutics, Inc.","symbol":"PSTX"},"owners":[{"id":84286,"kind":"person","name":"Gergen Mark J","position":1,"cik":"0001373110","reported_name":"Gergen Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-02-03T16:16:46.000Z","date":"2023-02-01","kind":"tax_withholding","acquired":false,"shares":31819,"price":7,"value":222733.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a Restricted Stock Unit Award granted to the Reporting Person on February 1, 2022."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 3,000 shares acquired by the Reporting Person under the Issuer's 2020 Employee Stock Purchase Plan (the \"ESPP\") on March 18, 2022 and 1,933 shares acquired by the Reporting Person under the ESPP on September 20, 2022."}],"balance_after":330314,"source":{"system":"sec-edgar","filing":"0001209191-23-006818","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1661460/000120919123006818/doc4.xml","form_type":"4"}},{"id":2419265,"issuer":{"id":84243,"kind":"organization","name":"Poseida Therapeutics, Inc.","symbol":"PSTX"},"owners":[{"id":84286,"kind":"person","name":"Gergen Mark J","position":1,"cik":"0001373110","reported_name":"Gergen Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-01T21:49:24.000Z","date":"2022-02-01","kind":"grant","acquired":true,"shares":518500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"12.5% of the shares subject to the stock option will vest and become exercisable on the first anniversary of the grant date listed in column 3 above, and the remaining shares will vest in 42 equal monthly installments thereafter."}],"balance_after":518500,"derivative":{"exercise_price":4.75,"expiration_date":"2032-01-31","underlying":"Common Stock","underlying_shares":518500},"source":{"system":"sec-edgar","filing":"0001209191-22-006171","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1661460/000120919122006171/doc4.xml","form_type":"4"}},{"id":2419264,"issuer":{"id":84243,"kind":"organization","name":"Poseida Therapeutics, Inc.","symbol":"PSTX"},"owners":[{"id":84286,"kind":"person","name":"Gergen Mark J","position":1,"cik":"0001373110","reported_name":"Gergen Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-02-01T21:49:24.000Z","date":"2022-02-01","kind":"grant","acquired":true,"shares":357200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares issuable upon the vesting of restricted stock units granted pursuant to the Issuer's Equity Incentive Plan. The RSUs are scheduled to vest in four equal annual installments."}],"balance_after":357200,"source":{"system":"sec-edgar","filing":"0001209191-22-006171","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1661460/000120919122006171/doc4.xml","form_type":"4"}},{"id":2876649,"issuer":{"id":84243,"kind":"organization","name":"Poseida Therapeutics, Inc.","symbol":"PSTX"},"owners":[{"id":84286,"kind":"person","name":"Gergen Mark J","position":1,"cik":"0001373110","reported_name":"Gergen Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CBO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-02-05T16:52:12.000Z","date":"2021-02-04","kind":"grant","acquired":true,"shares":342000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"12.5% of the shares subject to the stock option will vest and become exercisable on the six-month anniversary of the grant date listed in column 3 above, and the remaining shares will vest in 42 equal monthly installments thereafter."}],"balance_after":342000,"derivative":{"exercise_price":9.15,"expiration_date":"2031-02-03","underlying":"Common Stock","underlying_shares":342000},"source":{"system":"sec-edgar","filing":"0001209191-21-008131","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1661460/000120919121008131/doc4.xml","form_type":"4"}},{"id":3084375,"issuer":{"id":84243,"kind":"organization","name":"Poseida Therapeutics, Inc.","symbol":"PSTX"},"owners":[{"id":84286,"kind":"person","name":"Gergen Mark J","position":1,"cik":"0001373110","reported_name":"Gergen Mark J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CBO"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-07-13T19:00:16.000Z","date":"2020-07-09","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"12.5% of the shares subject to the stock option will vest and become exercisable on the 6 month anniversary of the grant date listed in column 3 above, and the remaining shares will vest in 42 equal monthly installments thereafter."}],"balance_after":75000,"derivative":{"exercise_price":16,"expiration_date":"2030-07-08","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001209191-20-042315","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1661460/000120919120042315/doc4.xml","form_type":"4"}},{"id":4424933,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":84286,"kind":"person","name":"Gergen Mark J","position":1,"cik":"0001373110","reported_name":"Gergen Mark J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Operating Officer"}}],"security":"Restricted Stock Units","published_at":"2017-02-24T21:05:43.000Z","date":"2017-02-22","kind":"grant","acquired":true,"shares":45568,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter."}],"balance_after":45568,"derivative":{"exercise_price":0,"exercise_date":"2018-02-22","underlying":"Common Stock","underlying_shares":45568},"source":{"system":"sec-edgar","filing":"0001179110-17-003118","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000117911017003118/edgar.xml","form_type":"4"}},{"id":4424932,"issuer":{"id":793,"kind":"organization","name":"HALOZYME THERAPEUTICS, INC.","symbol":"HALO"},"owners":[{"id":84286,"kind":"person","name":"Gergen Mark J","position":1,"cik":"0001373110","reported_name":"Gergen Mark J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Operating Officer"}}],"security":"Option to Purchase Common Stock","published_at":"2017-02-24T21:05:43.000Z","date":"2017-02-22","kind":"grant","acquired":true,"shares":72925,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests one-fourth on such date and then 1/48th monthly thereafter."}],"balance_after":72925,"derivative":{"exercise_price":12.07,"exercise_date":"2018-02-22","expiration_date":"2027-02-22","underlying":"Common Stock","underlying_shares":72925},"source":{"system":"sec-edgar","filing":"0001179110-17-003118","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1159036/000117911017003118/edgar.xml","form_type":"4"}}]}